Carbonic anhydrase inhibitors: Inhibition of transmembrane, tumor-associated isozyme IX, and cytosolic Isozymes I and II with aliphatic sulfamates

被引:80
作者
Winum, JY
Vullo, D
Casini, A
Montero, JL
Scozzafava, A
Supuran, CT
机构
[1] Univ Montpellier 2, Ecole Natl Super Chim Montpellier, Lab Chim Biomol, UMR 5032, F-34296 Montpellier, France
[2] Univ Florence, Chim Bioorgan Lab, Dipartimento Chim, I-50019 Florence, Italy
关键词
D O I
10.1021/jm030911u
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
series of aliphatic sulfamates and related derivatives incorporating cyclic/polycyclic (steroidal) moieties in their molecules has been synthesized and assayed as inhibitors of the zinc enzyme carbonic anhydrase (CA) and, more precisely, of the cytosolic isozymes CA I and II and the transmembrane, tumor-associated isozyme CA IX. The most potent CA I inhibitor was n-tetradecyl sulfamate and some (substituted)benzyl/phenethyl sulfamates (inhibition constants in the low micromolar range). Against CA II, low nanomolar inhibitors (0.7-3.4 nM) were n-decyl sulfamate and the (substituted)benzyl/phenethyl derivatives mentioned above. Effective CA II inhibition was also observed for the hydroxy/keto derivatives of dehydroepiandrosterone sulfamate. Efficient CA IX inhibitory properties, with inhibition constants in the range of 9-23 nM, were observed for the aliphatic sulfamates C-10-C-16 (with the most potent inhibitor being the n-dodecyl derivative) and the (substituted)benzyl/phenethyl sulfamates. The inhibition profile of the three investigated isozymes with this type of compound was rather different, allowing us to hope that the preparation of CA IX-selective inhibitors is possible (selectivity ratios toward hCA IX versus hCA II in the range of 5-63 has been observed for some of these compounds, whereas for the clinically used sulfonamides this parameter is in the range of 0.23-0.51). These data are critical for the design of novel antitumor therapies, mainly for hypoxic tumors that overexpress CA IX, which are nonresponsive to radiation or chemotherapy.
引用
收藏
页码:5471 / 5477
页数:7
相关论文
共 32 条
[1]   Evidence for the mechanism of the irreversible inhibition of oestrone sulphatase (ES) by aminosulphonate based compounds [J].
Ahmed, S ;
Owen, CP ;
James, K ;
Patel, CK ;
Sampson, L .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2002, 80 (4-5) :429-440
[2]   Review of estrone sulfatase and its inhibitors - An important new target against hormone dependent breast cancer [J].
Ahmed, S ;
Owen, CP ;
James, K ;
Sampson, L ;
Patel, CK .
CURRENT MEDICINAL CHEMISTRY, 2002, 9 (02) :263-273
[3]   ZUR KENNTNIS DER AMIDOSCHWEFELSAUREESTER [J].
APPEL, R ;
SENKPIEL, W .
ZEITSCHRIFT FUR ANORGANISCHE UND ALLGEMEINE CHEMIE, 1961, 310 (1-2) :94-99
[4]   HYDRAZINSULFONSAURE-AMIDE .1. UBER DAS HYDRAZODISULFAMID [J].
APPEL, R ;
BERGER, G .
CHEMISCHE BERICHTE-RECUEIL, 1958, 91 (06) :1339-1341
[5]   FINE TUNING OF THE CATALYTIC PROPERTIES OF CARBONIC-ANHYDRASE - STUDIES OF A THR200-] HIS VARIANT OF HUMAN ISOENZYME-II [J].
BEHRAVAN, G ;
JONSSON, BH ;
LINDSKOG, S .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1990, 190 (02) :351-357
[6]   Sulfonamides and Sulfonylated Derivatives as Anticancer Agents [J].
Casini, Angela ;
Scozzafava, Andrea ;
Mastrolorenzo, Antonio ;
Supuran, Claudiu T. .
CURRENT CANCER DRUG TARGETS, 2002, 2 (01) :55-75
[7]  
Chegwidden WR, 2001, GENE FAMILIES STUDIE, P157
[8]   Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, cancer-associated isozyme IX with lipophilic sulfonamides [J].
Franchi, M ;
Vullo, D ;
Gallori, E ;
Pastorek, J ;
Russo, A ;
Scozzafava, A ;
Pastorekova, S ;
Supuran, CT .
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2003, 18 (04) :333-338
[9]   Inhibition of carbonic anhydrase II by steroidal and non-steroidal sulphamates [J].
Ho, YT ;
Purohit, A ;
Vicker, N ;
Newman, SP ;
Robinson, JJ ;
Leese, MP ;
Ganeshapillai, D ;
Woo, LWL ;
Potter, BVL ;
Reed, MJ .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 305 (04) :909-914
[10]   Tumor hypoxia:: Definitions and current clinical, biologic, and molecular aspects [J].
Höckel, M ;
Vaupel, P .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (04) :266-276